The nation of Zimbabwe has turned down a significant American health deal valued at $367m (£272m) over five years because of the United States' insistence on confidential biological samples.
This rejection became public after a official document dated December was leaked, which showed President Emmerson Mnangagwa deemed the arrangement was "lopsided".
A government spokesperson has since clarified that the US was requesting genetic material for research and commercial gain but was unwilling to share the benefits from future vaccines.
"We will now turn to the difficult and regrettable process of winding down our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had donated over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has appealed for more negotiations to reach a deal agreeable to both sides so the nation's critical HIV programme can continue.
Wider Implications
Zimbabwe's decision comes after a comparable situation in Kenya, where a court suspended a related deal with the US after concerns were filed about the safety of citizens' health data.
After resuming office recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
The agency had overseen assistance for the US government, but Trump argued its expenditure was "inefficient" and his government was seeking direct bilateral agreements to boost transparency and responsibility.
Based on reports, Sixteen African countries have so far agreed to these new health pacts, representing over $18.3bn in new funding.
Details of the Declined Deal
The money for Zimbabwe would have supported "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this partnership would have delivered extraordinary advantages for Zimbabwean communities, especially the 1.2 million currently on HIV treatment via US-supported initiatives," Tremont commented.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"Our nation was requested to provide its genetic material and health information over an extended period, without any equivalent guarantee of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could result from that provided information," his statement read.
"Put simply, our country would supply the basic resources for medical research without any certainty that the resulting innovations would be available to our people should a new pandemic arise."
Sovereignty and International Frameworks
He also said that the US's withdrawal from the global health body and its pursuit of one-on-one deals were undermining frameworks already established via the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to manage potential pandemics.
"This mechanism is intended to guarantee that when a country provides its samples, the resulting advantages – including medicines and cures – are shared equitably, not commercialised exclusively by those with the funds to create them."
Zimbabwe's reservations regarding the US deal "are not meant as anti-American sentiment," he added.
"We welcome continued dialogue with our US partners on how future collaboration might be arranged in a way that honours the independence and interests of each country."
Health Experts Reaction
A leading public health body said it acknowledged the official position, but recommended that talks should continue since a large portion of the country's Aids initiatives were funded by external financing.
"If specific concerns arise, such as those involving information security or agreement terms, these can often be resolved through detailed discussion and mutually agreed protections," it added.
The situation highlights the continuing tensions between accepting vital foreign assistance and safeguarding national sovereignty in an increasingly interconnected world.